We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report.
- Authors
Di Palma, Martina; Gentilini, Elio; Masucci, Chiara; Micozzi, Alessandra; Turriziani, Ombretta; Mulè, Antonino; Foà, Robin; Martelli, Maurizio; D'Ettorre, Gabriella; Capria, Saveria; Chiaretti, Sabina
- Abstract
Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.
- Subjects
CONVALESCENT plasma; COVID-19; COVID-19 treatment; LYMPHOBLASTIC leukemia; ACUTE leukemia
- Publication
Mediterranean Journal of Hematology & Infectious Diseases, 2022, Vol 14, Issue 1, p1
- ISSN
2035-3006
- Publication type
Case Study
- DOI
10.4084/MJHID.2022.043